Globe Newswire

Activity Report for Quarter Ended June 30, 2025 (Appendix 4C)

NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales of Ryoncil^® (remestemcel-L-rknd) through the first quarter post product launch.

Ryoncil^® is the first and only FDA approved mesenchymal stromal cell (MSC) product in the Unites States and became commercially available for purchase on March 28, 2025, within one quarter of receiving FDA approval for treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children.

Mesoblast Chief Executive Dr. Silviu Itescu said, “We are pleased with the commercial launch activities of Ryoncil^® in the first quarter post-launch and look forward to updating on the current quarter’s progress now that mandatory state CMS coverage has become effective as of July 1, and we complete onboarding of the remaining major U.S. transplant centers.”

FINANCIAL HIGHLIGHTS FOR QUARTER ENDED JUNE 30, 2025

• US$13.2 million gross revenue (unaudited) from sales of Ryoncil^® post-launch March 28 through to June 30.¹
• US$1.6 million revenue from royalties on sales of TEMCELL^® HS Inj.² sold in Japan by our licensee.
• US$16.6 million net operating cash spend for the quarter.
• US$162 million (A$247 million)³ cash on hand at June 30, 2025.

OPERATIONAL HIGHLIGHTS FOR RYONCIL^® IN SR-aGvHD

• Mesoblast has onboarded more than 25 transplant centers since product launch and expects during this quarter to complete the onboarding process across all 45 priority transplant centers that account for approximately 80% of U.S. pediatric transplants.
• Coverage for Ryoncil^® continues to expand with over 250 million US lives insured by commercial and government payers. Federal Medicaid coverage by Centers for Medicare and Medicaid (CMS) is in place and mandatory fee-for-service Medicaid coverage for Ryoncil^® became effective July 1 in all US states.
  • To assist patients and institutions with insurance coverage, financial assistance, and access programs, ensuring that no patient is left behind in receiving this potentially life-saving therapy, Mesoblast has established a patient access hub termed MyMesoblast™, where Ryoncil^® is available for ordering. Additional information is available on ryoncil.com, where valuable resources for healthcare providers, patients and caregivers can be found.
• During the quarter, Ryoncil^® received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for treatment of SR-aGvHD in pediatric patients 2 months of age and older. This period of statutory exclusivity means that the FDA will not approve another MSC product for this indication during the 7-year period from the approval of Ryoncil^®.
• Separately, Mesoblast has biologic exclusivity preventing another sponsor from referencing the Ryoncil^® biologic license application (BLA) until December 2036, twelve years from its first approval which would prevent market entry by a biosimilar.
• These statutory exclusivities are in addition to Mesoblast’s strong U.S. intellectual property position on MSC composition of matter, manufacturing and indications, including SR-aGvHD, that provide a commercial barrier to entry against competitors through 2044.
• In July, Mesoblast held a Type B meeting with FDA for Ryoncil^® to discuss a pivotal trial in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product’s label from children to adults with SR-aGvHD. Meeting minutes are expected in the coming weeks.

OPERATIONAL HIGHLIGHTS FOR REXLEMESTROCEL IN CHRONIC INFLAMMATORY HEART FAILURE AND LOW BACK PAIN

• Mesoblast met with FDA in June in follow-up to the successful Type B meeting in early 2024 where FDA stated that the results of the presented studies with Revascor^® in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation could support accelerated approval under the existing Regenerative Medicine Advanced Therapy (RMAT) designation for end-stage HFrEF patients with a left ventricular assist device (LVAD),
• Mesoblast and FDA are aligned on items required for filing a biologics license application (BLA) for Revascor^® regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval.
• The 300-patient randomized controlled confirmatory Phase 3 trial of Mesoblast’s second generation allogeneic, STRO3-immunoselected, and industrially manufactured stromal cell product candidate rexlemestrocel-L is actively enrolling in patients with chronic low back pain (CLBP) due to inflammatory degenerative disc disease (DDD) of less than five years duration at multiple sites across the U.S.

Other
Fees to Non-Executive Directors were US$71,577, consulting payments to Non-Executive Directors were US$122,767 and salary payments to full-time Executive Directors were US$267,465, detailed in Item 6 of the Appendix 4C cash flow report for the quarter.⁴ From August 2023 to July 2025, our Non-Executive Directors have voluntarily reduced cash payment of their fees by 50% and Executive Directors (our Chief Executive and Chief Medical Officers) reduced their base salaries by 30%, in lieu of accepting equity-based incentives.

A copy of the Appendix 4C – Quarterly Cash Flow Report for the fourth quarter FY2025 is available on the investor page of the company’s website www.mesoblast.com.

About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.

Mesoblast’s RYONCIL^® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.

Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.

About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.

About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.

Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
References / Footnotes

1. Includes initial inventory purchases by our distributor.
2. TEMCELL^® HS Inj. is a registered trademark of JCR Pharmaceuticals Co. Ltd.
3. Translated at 1A$:0.655US$ being the June 30, 2025 rate as reported by the Reserve Bank of Australia.
4. As required by ASX listing rule 4.7 and reported in Item 6 of the Appendix 4C, reported are the aggregated total payments to related parties being Executive Directors and Non-Executive Directors.

Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.

Release authorized by the Chief Executive.

For more information, please contact:

New Super PAC will advocate for property tax reform, public safety, and fiscal responsibility to improve quality of life for Illinois communities

Dr. Anosh Ahmed Image

CHICAGO, July 18, 2025 (GLOBE NEWSWIRE) — The Anosh Inc Foundation, led by respected Chicago-based physician and philanthropist Dr. Anosh Ahmed, today announced its intention to establish a new Super Political Action Committee (Super PAC) headquartered in Illinois. This strategic initiative aims to champion policies that reflect the foundation’s mission of promoting public safety, fiscal responsibility, and sustainable community development throughout the state.

The newly proposed Super PAC will focus its advocacy efforts on some of the most pressing issues affecting Illinois residents, including property tax reform, public safety, and the long-term financial impacts of state and local government programs. It is designed to serve as a civic engagement platform, empowering citizens, community leaders, and stakeholders to push for positive policy change.

“Many families across Illinois are experiencing increasing financial strain, rising property taxes, and public safety concerns,” said Dr. Anosh Ahmed, founder of the Anosh Inc Foundation. “Through this initiative, our foundation is expanding its mission to support policy solutions that promote economic opportunity, protect our communities, and ensure long-term financial stability for residents.”

The Super PAC will operate independently from any specific political campaign and will remain focused on issue-based advocacy. Its primary goal is to support candidates and legislation that reflect the foundation’s core values, especially those focused on the well-being and prosperity of working-class families and underserved communities in Illinois.

A key emphasis will be placed on building coalitions with local organizations, grassroots leaders, and policymakers to address challenges such as the disproportionate impact of property taxes, gaps in public safety, and financial inefficiencies in government programs. By taking a proactive stance in the public policy space, the Anosh Inc Foundation aims to help shape a future where Illinois families can thrive.

The foundation’s decision to launch a Super PAC comes as part of its broader effort to transition from direct community support into the policy and advocacy arena. Over the years, the Anosh Inc Foundation has led impactful initiatives in healthcare access, education, economic empowerment, and charitable outreach, particularly in underserved areas across the United States.

About the Anosh Inc Foundation

The Anosh Inc Foundation is a nonprofit organization based in Chicago and founded by Dr. Anosh Ahmed. Its mission is to create sustainable change in communities through direct action, strategic partnerships, and civic advocacy. The foundation supports initiatives in education, healthcare, and economic development.

Media Contact:
Sandra Gomez
+1 (346) 678-7004
legal@anoshinc.com
https://www.anoshinc.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1537f111-0baa-439e-9ac9-388d18f6bdc1

SEO Dashboard

AI Visibility Overview

Competitor Visibility

Brand Perception

Traffic Visibility

The AI Visibility Overview is setting a new standard for Generative Engine Optimization (GEO) by giving users unprecedented insight over how their brand appears in AI search engines

NEW YORK – Wix.com Ltd. (NASDAQ: WIX), the leading SaaS website builder platform globally¹, today announced the launch of its AI Visibility Overview, a new solution that goes beyond traditional SEO tools, positioning brands for discoverability in the emerging era of  large language models (LLM). As part of Wix’s broader Generative Engine Optimization (GEO) initiative, this tool empowers users to understand, monitor, and actively improve how their brand appears in LLM-based search engines, such as ChatGPT, Gemini, Perplexity, and Claude,  helping brands stay ahead as LLMs redefine the landscape of SEO and online discovery. Wix is the first CMS to offer this kind of AI visibility natively, setting a new benchmark for AI search optimization tools within website platforms.

As LLMs become a key gateway for users seeking information and making decisions, visibility in AI-generated responses is quickly becoming essential for online success. GEO offers visibility into how a brand is perceived and surfaced by leading AI models, transforming how businesses approach their presence in the age of generative AI. Fully integrated into Wix’s SEO suite and accessible through the Analytics dashboard, GEO reflects Wix’s response to the evolving nature of search, providing users with a wide view of how their brand and content are being surfaced and engaged with across AI-powered platforms.

Capabilities of the AI Visibility Overview include:

• Manage AI citations & visibility: Users can track how often their website is cited by AI platforms in response to relevant queries, as well as add, or remove questions to better reflect their business.
• Monitor brand sentiment across LLMs: GEO empowers users to stay informed on how their brand is perceived by analyzing sentiment, perception, and positioning in AI-generated content.
• Benchmark visibility and competitive context: Users can compare their AI visibility performance to competitors to gain a better understanding of how their visibility stacks up against industry peers, identify growth opportunities, and discover which other sources are being cited in similar contexts. 
• Measure AI-driven traffic & query volume: Users can see how much traffic is driven to their site from AI platforms, as well as how frequently people ask about their brand or services in these engines.

“GEO is SEO for the AI era, providing users an all‑new level of search visibility,” said Doreen Weissfelner, Head of Analytics at Wix. “We are empowering users to bring AI search into focus by giving them information on how their sites are being cited, perceived and surfaced by leading AI-platforms. Just as we’ve supported our users in optimizing for traditional search engines, we’re now equipping them to navigate and succeed in an AI-driven landscape.  With the AI Visibility Overview, businesses can finally see how they’re being represented – and take steps to increase visibility, influence perception, and drive real outcomes”

As part of its broader commitment to AI search readiness, Wix also offers some premium eCommerce users the ability to manage LLMs.txt – designed to help websites communicate directly with LLMs – further empowering them to stay optimized for emerging AI platforms. With platforms like ChatGPT and Gemini expanding tools for product listings, LLMs.txt works alongside dynamic shopping feeds to give LLMs richer data on sellers and products. This can boost visibility in AI-powered search experiences and help merchants reach millions of potential customers.

The AI Visibility Overview is available to users with a Wix Business Manager set to English and is gradually rolling out to additional languages. To learn more about Wix’s vision for AI, read the blog by Avishai Abrahami, Co-Founder and CEO of Wix, here.

About Wix.com Ltd.
Wix is the leading SaaS website builder platform¹ to create, manage and grow a digital presence. Founded  in 2006, Wix is a comprehensive platform providing users – self-creators, agencies, enterprises, and more – with industry-leading performance, security, AI capabilities and a reliable infrastructure. Offering a wide range of commerce and business solutions, advanced SEO and marketing tools, the platform enables users to take full ownership of their brand, their data and their relationships with their customers. With a focus on continuous innovation and delivery of new features and products, users can seamlessly build a powerful and high-end digital presence for themselves or their clients. 

For more about Wix, please visit our Press Room
Media Relations Contact:  PR@wix.com  

¹ Based on number of active live sites as reported by competitors’ figures, independent third-party data and internal data as of Q1 2025.

Attachments

• SEO Dashboard
• AI Visibility Overview
• Competitor Visibility
• Brand Perception
• Traffic Visibility

NEW YORK, NY, July 16, 2025 (GLOBE NEWSWIRE) — Guardforce AI Co., Limited (Nasdaq: GFAI, GFAIW) (“Guardforce AI” or the “Company”), a global integrated security solutions provider specializing in secured logistics, AI, and Robot-as-a-Service (RaaS), today announced it will officially launch its smart solutions during a high-profile rebranding event hosted by its subsidiary, Guardforce Cash Solutions Security (Thailand) Company Limited (“GFCS”), on Friday, July 25, 2025, in Bangkok, Thailand.

The event will mark a significant milestone in GFCS’s transformation strategy as it unveils a refreshed brand identity of GFCS along with its two updated solution: Smart Cash Solutions and Smart Retail Solutions. The event will also feature remarks from two company leaders: Olivia Wang, Chairwoman and CEO of Guardforce AI, who will outline the Company’s strategy to position GFCS as both a secure logistics provider and a trusted technology partner; and Kelvin Chu, Managing Director of GFCS Thailand, who will highlight GFCS’s operational momentum and growing partnerships. GFCS’s top clients and key regional stakeholders will be in attendance.

“We’ve implemented smart technologies, including robotics to AI-driven tools, to solve real-world challenges related to automation and operational efficiency,” said Lei (Olivia) Wang, Chairwoman and CEO of Guardforce AI. “At this event, we’ll share our vision for advancing business operations and driving AI-powered growth alongside our clients.”

About Guardforce AI Co., Ltd.

Guardforce AI Co., Limited (NASDAQ: GFAI/GFAIW) is an integrated solution provider, specializing in security solutions, and focusing on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing process, especially for the retail and travel industry in the Asia Pacific. Drawing on 42 years’ operational experience, a premiere long-term customer base, and well-established sales channels, Guardforce AI has built a robust foundation towards the next level of elevating tailored AI solutions and expanding globally. For more information, visit www.guardforceai.com Twitter: @Guardforceai.

Safe Harbor Statement

This press release contains statements that do not relate to historical facts but are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can generally (although not always) be identified by their use of terms and phrases such as anticipate, appear, believe, continue, could, estimate, expect, indicate, intend, may, plan, possible, predict, project, pursue, will, would and other similar terms and phrases, as well as the use of the future tense. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the business of the Company, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control, including the risks described in our registration statements and annual reports under the heading “Risk Factors” as filed with the Securities and Exchange Commission. Actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this press release speak only as of the date hereof. Unless otherwise required by law, we undertake no obligation to publicly update or revise these forward-looking statements, whether because of new information, future events or otherwise.

Investor Relations:
David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: gfai@crescendo-ir.com 
Tel: 212-671-1020

Guardforce AI Corporate Communications:
Hu Yu
Email: yu.hu@guardforceai.com 

SHANGHAI and HONG KONG, July 16, 2025 (GLOBE NEWSWIRE) — NETCLASS Technology INC (Nasdaq: NTCL; the “Company” or “NetClass”), a leading B2B smart education IT solutions provider with offices in Shanghai, Hong Kong, Singapore and Tokyo, today announced its successful bid for the prestigious “Smart Digital Campus Construction” project for Shanghai East China Model High School. Following a rigorous evaluation process by the tender committee and final approval from the procuring entity, NetClass was awarded the contract, with a total value of approximately CNY 3.38 million (US$0.47 million).

This significant win represents strong recognition from the esteemed Shanghai East China Model High School and the broader educational sector, of NetClass’s comprehensive capabilities in educational informatization. The project entails the design and implementation of an integrated suite of smart campus solutions, leveraging NetClass’s expertise in building intelligent, connected, and future-ready educational environments.

“This contract award is a testament to the strength of our solutions and our deep understanding of the evolving needs of the education sector,” said Dr. Jianbiao Dai, Chairman and Chief Executive Officer of NetClass. “We are honored that Shanghai East China Model High School has entrusted us to deliver a state-of-the-art smart digital campus. This project exemplifies our commitment to empowering educational institutions with technology that enhances learning, streamlines administration, and creates safer, more efficient environments. It is a milestone that reinforces our leadership in educational informatization and accelerates our strategic expansion into comprehensive digital campus solutions.”

The successful bid marks a breakthrough in NetClass’s strategic expansion into the rapidly growing market for digital-intelligent campus solutions. Securing this project with a leading educational institution underscores the Company’s innovative approach and technological prowess in transforming traditional educational infrastructure.

About NETCLASS TECHNOLOGY INC
NETCLASS TECHNOLOGY INC is a leading B2B smart education specialist with offices in Shanghai, Hong Kong, Singapore, and Tokyo, providing innovative IT solutions to schools, training institutions, corporations, public agencies, and other organizations. Our services include SaaS subscription services and application software development, with solutions spanning teaching and campus management, online teaching, examinations, epidemic prevention, data storage, EDC (Education Credit) blockchain systems, and lecturer evaluation services. Our mission is to deliver reliable, high-quality products that drive sustainable growth for our customers. For more information, please visit the Company’s website: https://ir.netclasstech.com

For investor and media inquiries, please contact:
NETCLASS TECHNOLOGY INC
Investor Relations
Email: ir@netclasstech.com

Jackson Lin
Lambert by LLYC
Phone: +1 (646) 717-4593
Email: jian.lin@llyc.global